romosozumab
Selected indexed studies
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (N Engl J Med, 2016) [PMID:27641143]
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. (N Engl J Med, 2017) [PMID:28892457]
- A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. (Osteoporos Int, 2022) [PMID:34432115]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. (2025) pubmed
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. (2017) pubmed
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (2016) pubmed
- A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. (2022) pubmed
- Romosozumab. (2012) pubmed
- Romosozumab in osteoporosis: yesterday, today and tomorrow. (2023) pubmed
- Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk. (2022) pubmed
- Romosozumab for the treatment of osteoporosis - a systematic review. (2025) pubmed
- Sequential and combination therapy with romosozumab. (2025) pubmed
- Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when? (2024) pubmed